LEXINGTON, Mass., July 29, 2020 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapy, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced it will provide an update on programs
and plans and release its second quarter 2020 financial results
before the market opens on Thursday, August
6, 2020. Agenus executives and thought leaders will host a
video conference call and webcast at 8:30
a.m. ET.
Topics to be discussed:
- Registration plans and strategy for balstilimab +/-
zalifrelimab
- Agenus & Betta Pharmaceuticals partnership
progress for China
- Clinical status/next steps for AGEN1181 (NextGen
CTLA-4) +/- balstilimab (anti-PD-1)
- Allogeneic iNKT cells potential breakthrough for
COVID-19 and cancer based on efficacy and cost
- Cell therapy and antibody combinations
preclinically show curative potential
- AGEN1223 & AGEN2373 clinical update and plans for
bali +/- zali combos
- Myeloid immune response modifiers (TIGIT bispecific &
other novel targets)
Live Call: Dial 1-844-492-3727 (U.S.) or
1-412-317-5118 (International)
Webcast: The call will be accessible from the
Company's website at
http://investor.agenusbio.com/presentation-webcasts or via
https://www.webcaster4.com/Webcast/Page/1556/35715. A replay
will be available approximately two hours after the call and will
remain available until November 7,
2020.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio.
Contact
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-rd-update--second-quarter-earnings-report-301102427.html
SOURCE Agenus Inc.